1. Ventyx will present at major healthcare conferences in September 2025. 2. Key executives will discuss their innovative therapies for autoimmune diseases. 3. The portfolio includes promising Phase 2 candidates addressing high unmet medical needs. 4. Webcasts will be available for investors post-conferences. 5. VTYX focuses on oral therapies for neurodegenerative and inflammatory diseases.
Participation in investor conferences typically boosts company visibility, possibly enhancing investor interest, as seen historically with biotech firms. Positive reception during these presentations can lead to increased stock demand.
The article highlights significant upcoming engagements that may drive investor attention and engagement. With VTYX's clinical advancements, these events are pivotal for generating interest.
The upcoming conferences in September will likely lead to immediate interest in VTYX's stock. Previous conference engagements have resulted in stock price surges for similar companies.
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the following upcoming investor conferences:
A webcast of the Wells Fargo presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for 90 days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.
Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that completed a Phase 2a study in Parkinson's disease and is in Phase 2 development for cardiometabolic disease. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor.
For more information on Ventyx, please visit our website at https://ventyxbio.com.
Investor Relations Contact:
Alex Schwartz
Vice President, Investor Relations and FP&A
Ventyx Biosciences, Inc.
IR@ventyxbio.com
